Core Viewpoint - Tiger Med has seen a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, indicating a positive market sentiment towards the company [1][4]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][4]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][4]. Fund Holdings - According to data, one fund under Everbright Pramerica holds a significant position in Tiger Med. The Everbright Pramerica Multi-Strategy Select 18-Month Mixed Fund (004457) held 700 shares in the fourth quarter, representing 0.24% of the fund's net value, ranking it as the ninth largest holding [2][5]. - The fund has realized a floating profit of approximately 1,778 CNY today and a total of 2,268 CNY during the three-day increase [2][5]. - The Everbright Pramerica Multi-Strategy Select 18-Month Mixed Fund was established on May 16, 2017, with a current size of 16.77 million CNY. Year-to-date returns are 0.89%, with a one-year return of 6.02%, and a cumulative return since inception of 43.92% [2][5]. Fund Manager Performance - The fund manager, Zhu Jiantao, has been in position for 1 year and 326 days, managing assets totaling 1.695 billion CNY, with the best return during his tenure being 58.56% and the worst being -0.26% [3][6]. - Co-manager Yao Shi has been in position for 3 years and 92 days, managing assets of 99.14 million CNY, with the best return of 13.48% and the worst of -4.18% during his tenure [3][6].
泰格医药股价涨5%,光大保德信基金旗下1只基金重仓,持有700股浮盈赚取1778元